ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

NCT00003892 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

NETWORK

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: ISIS 5132

Sponsor

NCIC Clinical Trials Group